Keravision Inc/DE – ‘8-K’ for 7/20/99 – EX-99.25

On:  Tuesday, 7/20/99   ·   For:  7/20/99   ·   Accession #:  946154-99-22   ·   File #:  0-26316

in

this entire Filing. an “Entity” Search.

Show

Documents searched

and

each “hit”. the 1st “hit”.

↓↑Hints

Current Report   —   Form 8-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                         3     10K 
 2: EX-99.25    News Release Dated 7/15/1999                           2±    10K 
 3: EX-99.26    News Release Dated 7/15/1999                           2±     9K 
 4: EX-99.27    News Release Dated 7/15/1999                           3     16K 

EX-99.25   —   News Release Dated 7/15/1999

EX-99.25
TOC
↑Top
Previous
Next
↓Bottom
Just 1st
 
                                                               Exhibit 99.25

KeraVision, Inc. Announces Intention to Make Offering of Common Stock           

FREMONT, CA (July 15, 1999) -- KeraVision, Inc. (Nasdaq: KERA) announced        
today that it filed a registration statement with the Securities and            
Exchange Commission with respect to a proposed public offering of four          
million shares of the company's common stock.                                   

All of the shares are to be issued and sold by KeraVision.  Proceeds            
from the sale of the shares will be used by KeraVision for sales and            
marketing efforts related to the U.S. launch of its proprietary vision          
correction product, Intacs (trademark); the development and clinical            
testing of products based on the Intacs technology; prepayment of short-        
term debt, and working capital and other general corporate purposes.            

The offering is to be made through an underwriting group managed by             
Donaldson, Lufkin & Jenrette; Dain Rauscher Wessels, a division of Dain         
Rauscher Inc.; Prudential Securities, and SG Cowen.                             

KeraVision, founded in 1986, is the developer of Intacs, the first FDA-         
approved non-laser option for surgically treating mild myopia                   
(nearsightedness).  Intacs are a safe and effective alternative to              
eyeglasses, contact lenses and vision correction surgeries that                 
permanently alter the eye's central optical zone.  The company's                
patented technology platform is also being developed for the possible           
treatment of other common vision problems including mild hyperopia              
(farsightedness) and astigmatism.                                               

A registration statement relating to the proposed securities offering           
has been filed with the Securities and Exchange Commission but has not          
yet become effective.  These securities may not be sold nor may offers          
to buy be accepted prior to the time the registration statement becomes         
effective.  This news release is not an offer to sell these securities          
or our solicitation of your offer to buy these securities in any                
jurisdiction in which that would not be permitted or legal.                     

A prospectus relating to these securities may be obtained from:                 

Donaldson, Lufkin & Jenrette                                                    
277 Park Ave.                                                                   
New York, NY 10172                                                              

Dain Rauscher Wessels                                                           
60 South Sixth Street                                                           
Minneapolis, MN  55402                                                          

Prudential Securities                                                           
111 8th Ave.                                                                    
New York, NY  10011                                                             

SG Cowen                                                                        
One Financial Square                                                            
New York, NY  10005                                                             

Note to Editors: Intacs are a registered trademark or trademark of              
KeraVision, Inc. in the U.S. and foreign countries                              

Contact:                                                                        

KeraVision, Inc., Fremont                                                       
Mark Fischer-Colbrie, 510/353-3000 (Investors)                                  
Mick Taylor, 510/353-3075 (Media)                                               
www.keravision.com                                                              
Fax on Demand, 800/448-8559                                                     

# # #                                                                           

Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘8-K’ Filing		Date		Other Filings
Filed on / For Period End:		7/20/99
		7/15/99		S-3
				List all Filings